Title:mRNA Expression Profile of SFKs and Involvement of SFKs in the Regulation of LPS-Induced Erk1/2 Signaling in PBMCs of Active BD Patients
Volume: 19
Issue: 6
Author(s): Sevgi Irtegun-Kandemir*, Irmak Icen-Taskin, Mehtap Bozkurt and Sevgi Kalkanli-Tas
Affiliation:
- Department of Medical Biology, Faculty of Medicine, Dicle University, Diyarbakir,Turkey
Keywords:
Behçet's disease, LPS, Mitogen-activated protein kinase, Src family kinases, PBMCs, TLR4.
Abstract:
Background: Behcet’s Disease (BD) is a multisystemic inflammatory disorder affecting
large vessels, lungs joints, gastrointestinal and neurological systems. The pathogenesis of BD remains
poorly understood. Identifying the key signaling pathway is crucial for a complete understanding of the
pathogenesis of BD.
Objective: The aim of this study was to determine mRNA expression level of Src family kinases
(SFKs) members and their involvement in lipopolysaccharide (LPS)-induced mitogen-activated protein
kinases (MAPKs) regulation in peripheral blood mononuclear cells (PBMCs) of active BD patients.
Methods: Twenty- five active BD patients and twenty-five healthy controls were included in the study.
PBMCs were isolated from total blood by density gradient centrifugation. The mRNA expression levels
of SFKs members were measured by real-time quantitative PCR (RT-qPCR). The effect of SFKs
activity on LPS-induced activation MAPKs (Erk1/2, p38 and JNK) was examined by Western blot.
Results: The mRNA expression levels of Hck, Src, Lyn, Yes and Fyn were found to be slightly decreased
in active BD patients compared to the control subjects, but a slight change in mRNA level of
SFKs members did not impact on protein levels and protein activity. LPS-induced Erk1/2 phosphorylation
was significantly increased in the absence of SFKs activity in active BD patients. However, inhibition
of SFKs activity had no effect on LPS-induced phosphorylation of p38 and JNK in both controls
and active BD patients.
Conclusion: SFKs downregulate LPS-induced Erk1/2 phosphorylation in PBMCs of active BD patients.